• HFO 1234ze formulation of AstraZeneca’s Breztri Aerosphere budesonide / glycopyrronium / formoterol MDI approved in Australia

  According to AstraZeneca, the Australian Therapeutic Goods Administration has approved a reformulated Breztri (Trixeo) Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI with Solstice‘s Solstice Air HFO-1234ze as the propellant. Breztri is approved in Australia for the treatment of… [Read more . . .]

• MHRA approves HFA 152a formulation of Chiesi’s Clenil Modulite beclametasone MDI

  Both Chiesi and the UK’s Medicines and Healthcare products Regulatory Agency have announced the MHRA’s approval of a reformulated Clenil Modulite beclometasone MDI for the treatment of asthma, marking the first approval of an MDI using Orbia‘s HFA 152a as… [Read more . . .]

• FDA approves pediatric use of Glenmark’s Ryaltris olopatadine / mometasone nasal spray for seasonal allergic rhinitis

  According to Glenmark, the FDA has approved the company’s sNDA to extend the use of Ryaltris olopatadine / mometasone nasal spray for the treatment of seasonal allergic rhinitis to patients aged 6 -12. Ryaltris was… [Read more . . .]

• Eli Lilly to acquire AtaiBeckley and its BPL-003 intranasal mebufotenin

  Eli Lilly and Company has agreed to pay approximately $2.8 billion up front and up to an additional $1 billion in milestone payments for pyschedelics developer AtaiBeckley, the companies said. AtaiBeckley’s lead candidate is BPL-003… [Read more . . .]

• SHS Capital acquires majority stake in Basic Pharma

  Dutch CDMO Basic Pharma announced that German investment firm SHS Capital has acquired a majority stake in the company, with the investment expected to support additional manufacturing capacity. The announcement highlights Basic Pharma’s development and… [Read more . . .]

• VaxDome partners with Matica Bio on development of intranasal antiviral / vaccine

• Sino Biopharm licenses TQC3721 inhaled PDE3/4 inhibitor to AstraZeneca, licenses Trelegy Ellipta and Anoro Ellipta from GSK

• ARS Pharma names Donn Casale as its new CEO

• Nebu-Flow joins Innovate UK Scaleup Programme

• Atisama and Monash University get AU $15 million for continued development of RB042 inhaled SSO therapy

More news . . .